Targeting SARS-CoV-2 papain-like protease in the postvaccine era

While vaccines remain at the forefront of global healthcare responses, pioneering therapeutics against SARS-CoV-2 are expected to fill the gaps for waning immunity. Rapid development and approval of orally available direct-acting antivirals targeting crucial SARS-CoV-2 proteins marked the beginning...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Trends in pharmacological sciences (Regular ed.) 2022-11, Vol.43 (11), p.906-919
Hauptverfasser:	Ton, Anh-Tien, Pandey, Mohit, Smith, Jason R., Ban, Fuqiang, Fernandez, Michael, Cherkasov, Artem
Format:	Artikel
Sprache:	eng
Schlagworte:	Antiviral Agents - pharmacology Antiviral Agents - therapeutic use artificial intelligence computer-aided drug design Coronavirus Papain-Like Proteases - antagonists & inhibitors COVID-19 COVID-19 Drug Treatment Humans Opinion papain-like protease SARS-CoV-2 small molecules
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!